K-Beauty clinical trials have devolved into a profit-driven circus where testing labs unbundle basic device metrics to inflate fees, while subject recycling and data manipulation threaten scientific validity. Domestic brands overspend on superficial device scores, whereas fast-growing brands opt for cost-effective user surveys. Overseas, lax clinical data poses catastrophic legal risks under post-market compliance systems like MoCRA (US) and CPNP (Europe).